


Desipramine

| | |
|---------------------------|---|
| Cat. No.: | HY-B1272A |
| CAS No.: | 50-47-5 |
| Molecular Formula: | C ₁₈ H ₂₂ N ₂ |
| Molecular Weight: | 266.38 |
| Target: | Adrenergic Receptor |
| Pathway: | GPCR/G Protein; Neuronal Signaling |
| Storage: | Please store the product under the recommended conditions in the Certificate of Analysis. |



BIOLOGICAL ACTIVITY

| | |
|-------------------------------------|--|
| Description | Desipramine is a tricyclic psychotic compound, possessing antidepressant activity. Desipramine inhibits the norepinephrine reuptake receptor in the central nervous system and reduces the sleep-related loss of genioglossus activity, can be used to research the improvement of pharyngeal collapsibility ^{[1][2]} . |
| IC₅₀ & Target | Norepinephrine Reuptake Receptor ^[1] |

CUSTOMER VALIDATION

- Glia. 2022 Jul 1.
- J Parkinson Dis. 2020;10(2):523-542.
- Pharmaceutics. 2022, 14(8), 1523.
- Inflammation. 2021 Mar 4.
- Neural Regen Res. 2021;16:1660-70.

See more customer validations on www.MedChemExpress.com

REFERENCES

- [1]. Garcia AS, et al. Autoreceptor-mediated inhibition of norepinephrine release in rat medial prefrontal cortex is maintained after chronic desipramine treatment. J Neurochem. 2004 Nov;91(3):683-93.
- [2]. Taranto-Montemurro L, et al. Desipramine improves upper airway collapsibility and reduces OSA severity in patients with minimal muscle compensation. Eur Respir J. 2016 Nov;48(5):1340-1350.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA